Daida Alberto Armas, Verónica Hernández García, Yanira Román Castillo, Juan Ramón Santana Ayala, Franc Capdevila Finestres, Arturo Hardisson de la Torre, Carmen Rubio Armendáriz
{"title":"在提供药品护理配药服务时使用苯二氮卓类药物的患者的风险特征。","authors":"Daida Alberto Armas, Verónica Hernández García, Yanira Román Castillo, Juan Ramón Santana Ayala, Franc Capdevila Finestres, Arturo Hardisson de la Torre, Carmen Rubio Armendáriz","doi":"10.3390/pharmacy12040120","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tolerance and dependence stand out as the most relevant risks observed during benzodiazepine (BZD) treatments.</p><p><strong>Objectives: </strong>To evaluate the degree of dependence of patients on BZD treatments using the Tyrer test; to define a profile of patients at risk of developing BZD dependence; and to discuss the role of the pharmaceutical care offered by the community pharmacy during dispensing.</p><p><strong>Methods: </strong>Prospective cross-sectional descriptive observational study (August 2020-February 2021) involving 127 patients using BZD. They voluntarily answered a questionnaire during the dispensing pharmaceutical care service. The study was evaluated and codified (code: DAA-CLO-2020-01) by the Spanish Agency for Drugs and Health Products (AEMPS), and statistical analysis was performed with SPSS 25.0.</p><p><strong>Results: </strong>19.05% of patients using BZD were suspected of suffering from BZD tolerance, and 77.88% of all patients were identified as being at a high risk of BZD dependence. The Tyrer test for dependence indicated a mean score of 5.59 out of 13 points. An 18-fold increased risk of developing dependence was detected in the case of coexistence of high anxiety or depression.</p><p><strong>Conclusions: </strong>The community pharmacy, through protocolized care practices and supported by tools such as the Tyrer test, can play a decisive role in the detection, prevention, and resolution of the risks associated with BZD treatments.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11359597/pdf/","citationCount":"0","resultStr":"{\"title\":\"Risk Characterization in Patients Using Benzodiazepines While Providing Pharmaceutical Care Dispensing Service.\",\"authors\":\"Daida Alberto Armas, Verónica Hernández García, Yanira Román Castillo, Juan Ramón Santana Ayala, Franc Capdevila Finestres, Arturo Hardisson de la Torre, Carmen Rubio Armendáriz\",\"doi\":\"10.3390/pharmacy12040120\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Tolerance and dependence stand out as the most relevant risks observed during benzodiazepine (BZD) treatments.</p><p><strong>Objectives: </strong>To evaluate the degree of dependence of patients on BZD treatments using the Tyrer test; to define a profile of patients at risk of developing BZD dependence; and to discuss the role of the pharmaceutical care offered by the community pharmacy during dispensing.</p><p><strong>Methods: </strong>Prospective cross-sectional descriptive observational study (August 2020-February 2021) involving 127 patients using BZD. They voluntarily answered a questionnaire during the dispensing pharmaceutical care service. The study was evaluated and codified (code: DAA-CLO-2020-01) by the Spanish Agency for Drugs and Health Products (AEMPS), and statistical analysis was performed with SPSS 25.0.</p><p><strong>Results: </strong>19.05% of patients using BZD were suspected of suffering from BZD tolerance, and 77.88% of all patients were identified as being at a high risk of BZD dependence. The Tyrer test for dependence indicated a mean score of 5.59 out of 13 points. An 18-fold increased risk of developing dependence was detected in the case of coexistence of high anxiety or depression.</p><p><strong>Conclusions: </strong>The community pharmacy, through protocolized care practices and supported by tools such as the Tyrer test, can play a decisive role in the detection, prevention, and resolution of the risks associated with BZD treatments.</p>\",\"PeriodicalId\":30544,\"journal\":{\"name\":\"Pharmacy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11359597/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/pharmacy12040120\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/pharmacy12040120","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Risk Characterization in Patients Using Benzodiazepines While Providing Pharmaceutical Care Dispensing Service.
Background: Tolerance and dependence stand out as the most relevant risks observed during benzodiazepine (BZD) treatments.
Objectives: To evaluate the degree of dependence of patients on BZD treatments using the Tyrer test; to define a profile of patients at risk of developing BZD dependence; and to discuss the role of the pharmaceutical care offered by the community pharmacy during dispensing.
Methods: Prospective cross-sectional descriptive observational study (August 2020-February 2021) involving 127 patients using BZD. They voluntarily answered a questionnaire during the dispensing pharmaceutical care service. The study was evaluated and codified (code: DAA-CLO-2020-01) by the Spanish Agency for Drugs and Health Products (AEMPS), and statistical analysis was performed with SPSS 25.0.
Results: 19.05% of patients using BZD were suspected of suffering from BZD tolerance, and 77.88% of all patients were identified as being at a high risk of BZD dependence. The Tyrer test for dependence indicated a mean score of 5.59 out of 13 points. An 18-fold increased risk of developing dependence was detected in the case of coexistence of high anxiety or depression.
Conclusions: The community pharmacy, through protocolized care practices and supported by tools such as the Tyrer test, can play a decisive role in the detection, prevention, and resolution of the risks associated with BZD treatments.